Ipratropium + Salbutamol 500mcg/2.5mg Solution for Inhalation 2.5mL [PRESCRIPTION REQUIRED]

REMINDER: A doctor&rsquo,s prescription is required to purchase this product. To avoid delay in delivery or cancellation of your order ,(before the item is SHIPPED), please email a copy of your prescription (.jpeg or .pdf file format) to ,OnlinePharmacy@watsons.com.ph ,with your order number after Checkout. Our pharmacist will also get in touch with you to validate your prescription. Please be ready to show your original prescription upon claiming/delivery of your order.

 ,

 ,

 ,

Used in the treatment of obstructive airway diseases.

Place of Origin

Philippines

Product Usage

Administer by oral inhalation via nebulization. Prepare the nebulizer for use. Remove the ampoule from the labeled strip by twisting and pulling. Hold the ampoule upright and twist off the cap; transfer the contents of the solution into the nebulizer reservoir. Use the nebulizer according to the instruction provided by the manufacturer. After use; discard any solution left in the reservoir and thoroughly clean the nebulizer. Since the Ipratropium bromide + Salbutamol (Pulmodual) solution contains no preservatives; it is important to use the content immediately after opening. A new ampoule should be used for each administration to avoid microbial contamination. Discard partly used; opened or damaged ampoule. Ipratropium bromide + Salbutamol (Pulmodual) solution for inhalation should not be mixed with other drugs in the same nebulizer.

Ingredients

Each 2.5mL nebule contains 500mcg of Ipratropium bromide (as monohydrate) and 2.5mg Salbuatmol (as sulfate).

Storage Information

Store at temperatures not exceeding 30°C. Protect from light.

Warnings

Ipratropium bromide + Salbutamol (Pulmodual) should be used with caution in patients with prostatic hypertrophy; bladder neck obstruction; narrow angle glaucoma; risk of paradoxical bronchospasm usually occurs with the first dose of nebulized solution; it should be inhaled under medical supervision; hyperthyroidism; cardiovascular disease; arrhythmias; susceptibility to QT-interval prolongation; hypertension and diabetes mellitus. Potentially serious hypokalaemia may result from beta2 agonist therapy; possibly through intracellular shunting; which can produce adverse cardiovascular effects. The decrease in serum potassium levels is usually transient; not requiring supplementation.

Width

1

Height

1

Depth

1